The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
Author:
Salmen Teodor1ORCID, Bobirca Florin-Teodor2ORCID, Bica Ioana-Cristina1ORCID, Mihai Doina-Andrada3, Pop Corina4, Stoian Anca Pantea3ORCID
Affiliation:
1. Doctoral School of Carol Davila, University of Medicine and Pharmacy, 050474 Bucharest, Romania 2. Department of General Surgery, Carol Davila, University of Medicine and Pharmacy, 050474 Bucharest, Romania 3. Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania 4. Department of Gastroenterology and Internal Medicine, Carol Davila, University of Medicine and Pharmacy, 050474 Bucharest, Romania
Abstract
Aim: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose-lowering drugs and drugs for the treatment of type 2 diabetes mellitus (T2DM), in a standard-of-care regimen with maximum tolerated doses, and, respectively, when compared with metformin. Methods: We conducted a retrospective, observational study on 405 patients that were seen in the outpatient clinic of the N Paulescu National Institute for Diabetes Mellitus, Bucharest, Romania, in 2019. Their demographics, metabolic parameters, and medication safety were evaluated at three follow-up visits, from baseline, six months, and twelve months. Results: Both SGLT-2is and GLP-1 RAs are safe regarding creatinine, eGFR, urea, GOT, and GPT upon the comparison of the data from the six- and twelve-month visits with the initial visit, and also the twelve-month visit with the six-month visit. Moreover, when comparing SGLT-2is and GLP-1 RAs with metformin, there are safety data only for urea. Conclusions: In this retrospective analysis, both SGLT-2is and GLP-1 RAs, when used in conjunction with other glucose-lowering, blood-pressure-lowering, and lipid-lowering medications, appeared to be safe for the management of T2DM.
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference74 articles.
1. Twin epidemics of COVID-19 and non-communicable disease;Sheldon;BMJ,2020 2. Lanuza, F., Zamora-Ros, R., Hidalgo-Liberona, N., Andrés-Lacueva, C., and Meroño, T. (2020). Wholegrain Consumption and Risk Factors for Cardiorenal Metabolic Diseases in Chile: A Cross-Sectional Analysis of 2016–2017 Health National Survey. Nutrients, 12. 3. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res. Clin. Pract.,2022 4. Dobrică, E.C., Găman, M.A., Cozma, M.A., Bratu, O.G., Pantea Stoian, A., and Diaconu, C.C. (2019). Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina, 55. 5. Drug-drug interactions in polypharmacy patients: The impact of renal impairment;Papotti;Curr. Res. Pharmacol. Drug Discov.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|